Shares of MBX Biosciences, Inc. (MBX) have gained 44% over the past four weeks to close the last trading session at $20, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $37.71 indicates a potential upside of 88.6%.The mean estimate comprises seven short-term price targets with a standard deviation of $4.23. While the lowest estimate of $30.00 indicates a 50% increase from the cu ...

Earnings Reports - AutoZone Inc. is expected to report quarterly earnings of $50.83 per share with revenue of $6.24 million [2] - Firefly Aerospace Inc. reported a second-quarter loss of $5.78 per share, an increase from a loss of $4.60 per share a year ago, with sales declining to $15.549 million from $21.071 million [2] - AAR Corp. is anticipated to post earnings of 98 cents per share on revenue of $688.72 million for the latest quarter [2] - Micron Technology Inc. is expected to report quarterly earnings of $2.86 per share with revenue of $11.22 billion [2] Stock Performance - AutoZone shares decreased by 0.5% to close at $4,121.00 [2] - Firefly Aerospace shares fell by 12.4% to $43.38 in after-hours trading [2] - AAR shares increased by 0.5% to $77.28 in after-hours trading [2] - MBX Biosciences Inc. shares declined by 2.1% to $19.58 in after-hours trading [2] - Micron shares rose by 1% to $166.30 in after-hours trading [2]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?It has been a good day for companies involved in peptide drug design and development. News broke this morning that Metsera and its portfolio of glucagon like peptide 1 receptor agonist ("GLP-1 RA") drugs is set to ...

Core Viewpoint - MBX Biosciences, Inc. has filed a registration statement for a proposed public offering of 10,000,000 shares of common stock, with an additional option for underwriters to purchase up to 1,500,000 shares [1][2][3] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders, utilizing its proprietary PEP™ platform [6] Offering Details - The public offering price has not yet been determined, and the offering is subject to market conditions [1] - J.P. Morgan, Jefferies, TD Cowen, and Guggenheim Securities are acting as joint book-running managers for the offering, with Citizens Capital Markets and Oppenheimer & Co. as co-lead managers [2] - The registration statement has been filed with the SEC but is not yet effective, meaning securities cannot be sold until it becomes effective [3] Prospectus Information - The proposed offering will be made only by means of a prospectus, which can be obtained from the respective financial institutions involved in the offering [4]

Core Insights - Guggenheim maintains a "Buy" rating for MBX Biosciences, raising the price target from $44 to $84, while the stock was priced at $10 at the time of the report [1][5] - MBX's treatment, Canvuparatide, has shown promising results in clinical trials, achieving a 63% responder rate at 12 weeks and a 79% rate at 6 months [2][5] - The stock price of MBX has surged by 105.05%, currently priced at $20.51, reflecting strong investor confidence [3][5] Company Performance - MBX's market capitalization is approximately $688.84 million, with a trading volume of 19,500,369 shares [4] - The company is preparing for a Phase 3 trial in 2026, which is a key factor contributing to its market position [4] - The stock has fluctuated between $20 and $26.45, with a 52-week high of $27.50 and a low of $4.81 [3]

Group 1 - U.S. stocks showed mixed performance, with the Dow Jones index declining over 100 points on Monday [1] - PROS Holdings, Inc. shares surged 40% to $22.97 following the announcement of its acquisition by Thoma Bravo [1] - MBX Biosciences, Inc. saw a significant increase of 144% to $24.40 after its once-weekly Canvuparatide met primary endpoints in a Phase 2 trial [3] - Metsera, Inc. gained 62.8% to $54.25 amid reports of a near acquisition deal with Pfizer [3] - Anywhere Real Estate Inc. experienced a 57% rise to $11.13 due to a combination announcement with Compass in an all-stock transaction [3] - The ODP Corporation's shares increased by 33.6% to $27.82 after announcing a definitive agreement to be acquired by an affiliate of Atlas Holdings [3] - Banco BBVA Argentina S.A. shares rose 17.7% to $9.64 following U.S. Treasury Secretary Bessent's statement of support for Argentina [3] - Grupo Supervielle S.A. also saw a 16% increase to $5.83 under similar circumstances regarding U.S. support for Argentina [3] - Lumen Technologies, Inc. rose 12.5% to $6.43 after announcing significant progress in building infrastructure for the AI economy [3] - IREN Limited gained 10.7% to $42.88 after doubling its AI Cloud capacity to 23,000 GPUs [3]

Summary of MBX Biosciences Conference Call - September 22, 2025 Company Overview - **Company**: MBX Biosciences - **Ticker**: NasdaqGS:MBX - **Focus**: Development of once-weekly candiparatide for the treatment of hypoparathyroidism (HP) Key Industry Insights - **Hypoparathyroidism**: A chronic condition affecting over 250,000 people in the U.S. and EU combined, primarily caused by a deficiency of parathyroid hormone (PTH) due to surgical removal of parathyroid glands [6][7] - **Market Opportunity**: The U.S. and EU represent a multibillion-dollar market opportunity for treatments addressing HP [30] Core Findings from AVAIL Phase II Clinical Trial - **Positive Results**: The trial demonstrated that 63% of patients receiving once-weekly candiparatide achieved the primary composite endpoint at week 12, compared to 31% on placebo, indicating a statistically significant difference [5][15] - **High Patient Retention**: 94% of patients completed the 12-week study and chose to continue into the open-label extension, reflecting strong patient enthusiasm for the treatment [5][19] - **Durability of Response**: In the ongoing open-label extension, responder rates increased to 79% at six months, suggesting potential durability of the treatment effect [19] - **Calcium Balance Restoration**: Urine calcium excretion was reduced in candiparatide-treated patients, indicating the therapy's ability to help restore calcium balance [6][18] Safety Profile - **Well Tolerated**: Once-weekly candiparatide was well tolerated, with no treatment-related serious adverse events or discontinuations reported during the 12-week trial [6][25] - **Adverse Events**: Commonly reported adverse events included headaches, hypercalcemia, arthralgia, and nausea, with hypercalcemia occurring in approximately 13% to 31% of patients depending on the dose [26][27] Future Development Plans - **Phase III Preparation**: The company plans to schedule an end-of-Phase II meeting with the FDA and begin dosing patients in a global Phase III registration trial in 2026 [31][32] - **Upcoming Presentations**: Data will be presented at the International Hypoparathyroidism Conference in October 2025 and at a major medical conference [31] Additional Considerations - **Patient-Centric Approach**: The once-weekly dosing regimen is expected to be preferred by both healthcare providers and patients due to its convenience compared to daily injections [30][31] - **Sensitivity Analysis**: A sensitivity analysis indicated that excluding patients with higher baseline PTH levels resulted in a placebo response of 15%, reinforcing the efficacy of candiparatide [38] Conclusion - **Best-in-Class Potential**: The results from the AVAIL Phase II trial strongly support the potential of once-weekly candiparatide to become a new standard of care for patients with hypoparathyroidism, addressing significant unmet medical needs in this patient population [28][30]

Phase 2 Trial and Open-Label Extension Top-Line Results: Once-Weekly Canvuparatide in Adults with Hypoparathyroidism September 22, 2025 Disclaimer This presentation includes forward looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our product candidates, preclinical study and/or clinical trial timelines, including projected data announcements, future results of operations and financial position, strategy and plans, in ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - AgriFORCE Growing Systems Ltd. (AGRI) has increased by 263% to $8.73 [3] - Qualigen Therapeutics, Inc. (QLGN) has risen by 212% to $8.87 [3] - Flora Growth Corp. (FLGC) is up 103% at $55.36 [3] - Boxlight Corporation (BOXL) has gained 102% to $3.16 [3] - Platinum Analytics Cayman Limited (PLTS) is up 96% at $14.00 [3] - Metsera, Inc. (MTSR) has increased by 59% to $52.99 [3] - Anywhere Real Estate Inc. (HOUS) is up 51% at $10.72 [3] - Fold Holdings, Inc. (FLD) has risen by 30% to $5.93 [3] - ARB IOT Group Limited (ARBB) is up 28% at $8.02 [3] - MBX Biosciences, Inc. (MBX) has increased by 26% to $12.64 [3] Premarket Losers - AlphaVest Acquisition Corp (ATMV) has decreased by 27% to $15.99 [4] - Helius Medical Technologies, Inc. (HSDT) is down 17% at $20.00 [4] - CEA Industries Inc. (BNC) has fallen by 15% to $8.20 [4] - Simpple Ltd. (SPPL) is down 13% at $5.00 [4] - FatPipe, Inc. (FATN) has decreased by 11% to $7.87 [4] - Tharimmune, Inc. (THAR) is down 11% at $3.20 [4] - Yueda Digital Holding (YDKG) has fallen by 11% to $2.98 [4] - American Battery Technology Company (ABAT) is down 10% at $2.94 [4] - AGM Group Holdings Inc. (AGMH) has decreased by 9% to $9.36 [4] - Antelope Enterprise Holdings Limited (AEHL) is down 5% at $3.38 [4]

Core Insights - MBX Biosciences announced that once-weekly canvuparatide achieved statistical significance in the primary endpoint at Week 12 of the Phase 2 Avail trial for chronic hypoparathyroidism, with 63% of treated patients meeting the endpoint compared to 31% in the placebo group [2][3][7] - The company is preparing to initiate a Phase 3 clinical trial in 2026 based on the positive results from the Avail trial [4][5] - Canvuparatide was well tolerated, with no serious adverse events reported during the 12-week trial [1][13] Phase 2 Avail Trial Results - In the 12-week trial, 63% of canvuparatide-treated patients achieved the primary composite endpoint, while 79% maintained responder status at 6 months in the open-label extension [3][7] - The primary endpoint involved maintaining serum calcium levels in the normal range (8.2–10.6 mg/dL) and independence from conventional therapy [3][7] - All 64 patients completed the 12-week study, and 94% chose to enter the open-label extension [2][11] Safety and Tolerability - Canvuparatide was generally well tolerated, with most treatment-emergent adverse events classified as mild or moderate [13] - Injection site reactions occurred in 19% of the treatment group compared to 13% in the placebo group, with no treatment-related serious adverse events reported [13] Future Development - The company plans to present additional data from the Phase 2 trial and open-label extension at an upcoming major medical meeting [9] - The results support the potential of canvuparatide as a best-in-class treatment for hypoparathyroidism, addressing significant unmet medical needs [5][15] About Hypoparathyroidism - Hypoparathyroidism is a rare endocrine disease affecting over 250,000 individuals in the U.S. and Europe, characterized by low calcium levels due to parathyroid hormone deficiency [12] - Current treatments primarily involve high doses of oral calcium and active vitamin D supplements, which do not address the underlying cause of the disease [12]